Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 Tablets in Otherwise Healthy Controlled Asthmatic Subjects (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs BI 1021958 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jul 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.